|
|
Blood, 15 July 2004, Vol. 104, No. 2, pp. 350-355.
Prepublished online as a Blood First Edition Paper on April 1, 2004; DOI 10.1182/blood-2004-01-0083.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Individualized risks of first adverse events in patients with Fanconi anemia
Philip S. Rosenberg,
Yi Huang, and
Blanche P. Alter
From the Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD; the Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; the Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD.
Fanconi anemia (FA) is an autosomal recessive condition associated with bone marrow failure (BMF) leading to death or hematopoietic stem cell transplantation, acute myeloid leukemia (AML), and solid tumors (STs). It is unclear which patients are most likely to develop each outcome. From a cohort of 144 North American patients with FA, we calculated individualized risks of each outcome, given the presence or absence of readily diagnosed congenital abnormalities that occur frequently in FA. Abnormal radii and a 5-item congenital abnormality score were significant risk factors for BMF. The cumulative incidence of BMF by age 10 years varied from 18% in the lowest BMF risk group to 83% in the highest. Because of competing risks, patients in the lowest BMF risk group were most likely to live long enough to develop AML or ST, and, conversely, patients in the highest BMF risk group were least likely to live long enough to develop AML or ST. By age 40, the cumulative incidence of ST ranged from 0.6% to 29% in the highest and lowest BMF risk groups, respectively. Abnormal radii are the strongest predictor of early BMF in FA; a congenital abnormality score separates patients with normal radii into distinct prognostic groups. (Blood. 2004;104:350-355)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. P. Alter, N. Giri, S. A. Savage, and P. S. Rosenberg
Cancer in dyskeratosis congenita
Blood,
June 25, 2009;
113(26):
6549 - 6557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Rosenberg, B. P. Alter, and W. Ebell
Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry
Haematologica,
April 1, 2008;
93(4):
511 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Alter
Diagnosis, Genetics, and Management of Inherited Bone Marrow Failure Syndromes
Hematology,
January 1, 2007;
2007(1):
29 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Alter, H. Joenje, A. B. Oostra, and G. Pals
Fanconi Anemia: Adult Head and Neck Cancer and Hematopoietic Mosaicism
Arch Otolaryngol Head Neck Surg,
July 1, 2005;
131(7):
635 - 639.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Van Waes
Head and Neck Squamous Cell Carcinoma in Patients With Fanconi Anemia
Arch Otolaryngol Head Neck Surg,
July 1, 2005;
131(7):
640 - 641.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Soulier, T. Leblanc, J. Larghero, H. Dastot, A. Shimamura, P. Guardiola, H. Esperou, C. Ferry, C. Jubert, J.-P. Feugeas, et al.
Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway
Blood,
February 1, 2005;
105(3):
1329 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Alter
Bone Marrow Failure: A Child Is Not Just a Small Adult (But an Adult Can Have a Childhood Disease)
Hematology,
January 1, 2005;
2005(1):
96 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
